Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC

Renaissance Technologies LLC lessened its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 14.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,443 shares of the company’s stock after selling 2,000 shares during the quarter. Renaissance Technologies LLC owned about 0.32% of Aligos Therapeutics worth $456,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AlphaMark Advisors LLC boosted its stake in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Aligos Therapeutics by 19.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after acquiring an additional 2,306 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in Aligos Therapeutics in the 4th quarter valued at about $107,000. Geode Capital Management LLC grew its stake in shares of Aligos Therapeutics by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company’s stock worth $1,086,000 after purchasing an additional 3,197 shares during the last quarter. Finally, Wells Fargo & Company MN bought a new stake in shares of Aligos Therapeutics in the 4th quarter worth approximately $869,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Down 7.1 %

Shares of Aligos Therapeutics stock opened at $5.60 on Friday. Aligos Therapeutics, Inc. has a 12-month low of $3.76 and a 12-month high of $46.80. The firm has a market capitalization of $34.24 million, a PE ratio of -0.42 and a beta of 2.72. The stock’s fifty day moving average is $8.54 and its 200-day moving average is $19.41.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.63) by ($10.45). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the previous year, the firm posted ($5.50) EPS. Analysts expect that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Aligos Therapeutics in a report on Monday, March 31st.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).